Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Tokyo - Delayed Quote JPY

GENOVA, Inc. (9341.T)

Compare
911.00
-36.00
(-3.80%)
At close: April 4 at 3:30:00 PM GMT+9
Loading Chart for 9341.T
  • Previous Close 947.00
  • Open 932.00
  • Bid 911.00 x --
  • Ask 913.00 x --
  • Day's Range 885.00 - 932.00
  • 52 Week Range 885.00 - 1,975.00
  • Volume 247,400
  • Avg. Volume 150,688
  • Market Cap (intraday) 15.764B
  • Beta (5Y Monthly) -0.49
  • PE Ratio (TTM) 8.53
  • EPS (TTM) 106.86
  • Earnings Date Feb 13, 2025
  • Forward Dividend & Yield 20.00 (2.20%)
  • Ex-Dividend Date Mar 28, 2025
  • 1y Target Est --

GENOVA, Inc. engages in the medical platform and smart clinic businesses in Japan. It offers Medical Doc, a platform that distributes articles for medical institutions, patient experience articles, treatment videos, and medical-related articles. It also provides Smart Clinic, an online medical treatment and consultation service, which offers medical treatment at home or work for users without going to a hospital. In addition, the company offers NOMOCa-Stand, a smart and simple automatic payment and reception machine; NOMOCa-Regi, a self-pay machine dedicated to the clinic; and CLINIC BOT, an AI Chatbot System. The company was founded in 2005 and is headquartered in Tokyo, Japan.

www.genova.co.jp

352

Full Time Employees

March 31

Fiscal Year Ends

Recent News: 9341.T

View More

Performance Overview: 9341.T

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

9341.T
29.24%
Nikkei 225 (^N225)
15.33%

1-Year Return

9341.T
33.11%
Nikkei 225 (^N225)
15.07%

3-Year Return

9341.T
48.24%
Nikkei 225 (^N225)
21.79%

5-Year Return

9341.T
48.24%
Nikkei 225 (^N225)
89.56%

Compare To: 9341.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 9341.T

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    15.76B

  • Enterprise Value

    9.82B

  • Trailing P/E

    8.53

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.66

  • Price/Book (mrq)

    2.27

  • Enterprise Value/Revenue

    1.00

  • Enterprise Value/EBITDA

    3.71

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    18.30%

  • Return on Assets (ttm)

    20.10%

  • Return on Equity (ttm)

    30.13%

  • Revenue (ttm)

    10.19B

  • Net Income Avi to Common (ttm)

    1.86B

  • Diluted EPS (ttm)

    106.86

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.08B

  • Total Debt/Equity (mrq)

    0.46%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 9341.T

View More

Company Insights: 9341.T

Research Reports: 9341.T

View More

People Also Watch